Ophthotech Corp  

(Public, NASDAQ:OPHT)   Watch this stock  
Find more results for Kathy Wood´┐Ż
43.52
-0.51 (-1.16%)
Real-time:   12:15PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 42.90 - 43.96
52 week 36.46 - 72.51
Open 42.95
Vol / Avg. 102,558.00/461,909.00
Mkt cap 1.53B
P/E     -
Div/yield     -
EPS -2.19
Shares 34.74M
Beta     -
Inst. own 94%
Nov 9, 2015
Q3 2015 Ophthotech Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 5, 2015
Q2 2015 Ophthotech Corp Earnings Release
Aug 5, 2015
Q2 2015 Ophthotech Corp Earnings Call
Jun 10, 2015
Ophthotech Corp at Goldman Sachs Healthcare Conference
Jun 4, 2015
Ophthotech Corp Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -2325.05% -283.02%
Operating margin -2656.29% -195.14%
EBITD margin - -194.83%
Return on average assets -30.71% -33.48%
Return on average equity -116.44% -78.30%
Employees 72 -
CDP Score - -

Address

1 Penn Plz Fl 19
NEW YORK, NY 10119-0002
United States - Map
+1-212-8458200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ophthotech Corporation is a United States-based biopharmaceutical company. The Company is engaged in developing and commercializing therapies for the treatment of diseases of the eye and focuses on developing therapeutics for age-related macular degeneration (AMD). Its product pipeline includes Fovista anti-platelet derived growth factor (PDGF) therapy, which is in Phase III clinical trials for use in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in wet AMD. It prevents PDGF from binding to its natural receptor on pericytes, thus causing pericytes to be stripped from newly formed abnormal blood vessels.Its second product candidate, Zimura, an inhibitor of complement factor C5, is developed for the treatment of geographic atrophy (a form of dry AMD) and, in combination with anti-VEGF therapy and Fovista, for the treatment of wet AMD. Both Fovista and Zimura are aptamers, single strands of nucleic acid that binds with affinity to targets.

Officers and directors

David R. Guyer Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Samir C. Patel M.D. Vice Chairman of the Board, President
Age: 54
Bio & Compensation  - Reuters
Barbara Wood Senior Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Douglas K. Kollmorgen Senior Vice President - Quality Assurance
Bio & Compensation  - Reuters
Harvey N. Masonson M.D. Senior Vice President - Clinical Development
Bio & Compensation  - Reuters
Loni da Silva Senior Vice President - Global Regulatory Affairs
Bio & Compensation  - Reuters
Todd N. Smith Senior Vice President, Chief Commercial Officer
Age: 45
Bio & Compensation  - Reuters
Kathy Galante Vice President of Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
Douglas G. Brooks Ph.D. Vice President - Manufacturing Development
Bio & Compensation  - Reuters
Jeffrey Nau Vice President - Clinical and Medical Affairs
Bio & Compensation  - Reuters